FDA Clears First Drug for Parkinson's Dyskinesia FDA Clears First Drug for Parkinson's Dyskinesia
The FDA has approved the first drug for treatment of dyskinesia in patients with Parkinson ' s disease dyskinesia, fulfilling an"unmet need" in PD management, experts say.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 24, 2017 Category: Drugs & Pharmacology Source Type: news

Adamas Pharma secures approval for Parkinson's dyskinesia drug
(Reuters) - The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading. (Source: Reuters: Health)
Source: Reuters: Health - August 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Diabetes drug may be helpful for Parkinson's disease
Conclusion This research shows some interesting early findings, though the magnitude of effect was very small compared to the improvements in symptoms with current dopaminergic drugs. The study was well conducted but did have some limitations: The number of people taking part was quite small. This may have meant it was hard to detect any other benefits or harms of taking the drug other than the effects on motor scores. The period of time people were given the drug and followed up meant that longer-term effects could not be measured. The benefit of the drug observed so far might not be big enough to make a differen...
Source: NHS News Feed - August 4, 2017 Category: Consumer Health News Tags: Neurology Source Type: news

Drug Eases Tardive Dyskinesia Linked to Antipsychotic Use Drug Eases Tardive Dyskinesia Linked to Antipsychotic Use
Deutetrabenazine significantly reduced abnormal involuntary movements in patients with tardive dyskinesia caused by antipsychotic drugs in a phase 3 study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Second Tardive Dyskinesia Drug Works (CME/CE)
(MedPage Today) -- Deutetrabenazine in line to be second VMAT-2 inhibitor OK ' d for the condition (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 1, 2017 Category: Psychiatry Source Type: news

Extended-Release Amantadine Effective for Dyskinesia in PD Extended-Release Amantadine Effective for Dyskinesia in PD
A phase 3 study shows a once-daily formulation of amantadine is superior to placebo in reducing severity and duration of levodopa-induced dyskinesia in patients with Parkinson ' s.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New Amantadine Pill Cuts Dyskinesia in Parkinson's (CME/CE)
(MedPage Today) -- But questions about cost-effectiveness remain (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 12, 2017 Category: Consumer Health News Source Type: news

Drug reduces dyskinesia, 'off' times in Parkinson's patients
(Reuters Health) - An experimental extended-release version of the drug amantadine can reduce the duration of the involuntary dancing-like movements seen in people whose long-term use of levodopa has kept their Parkinson ’s disease under control. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New Drug Safe, Effective for Tardive Dyskinesia New Drug Safe, Effective for Tardive Dyskinesia
Phase 3 trials showed improved movement and quality-of-life scores for deutetrabenazine-treated patients with tardive dyskinesia, leading the FDA to grant priority review and an August 30 target date.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Valbenazine for Tardive Dyskinesia Tolerated Long-Term
(MedPage Today) -- Only 15% of patients discontinued tx over 1 year due to adverse events (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - May 29, 2017 Category: General Medicine Source Type: news

Valbenazine Approval Highlights Lessons for Researchers Valbenazine Approval Highlights Lessons for Researchers
A New England Journal of Medicine editorial notes that the recent FDA approval of valbenazine for tardive dyskinesia shows how to effectively and quickly develop a much-needed treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 11, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

NeuroBreak: $63,000 Question for Tardive Dyskinesia; Sacco Leads AAN
(MedPage Today) -- News and commentary from the world of neurology and neuroscience (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 2, 2017 Category: Psychiatry Source Type: news

ICER to review treatments for tardive dyskinesia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2017 Category: Drugs & Pharmacology Source Type: news

Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations SAN DIEGO, April 21, 2017 -- (Healthcare Sales & Marketing Network) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announ... Biopharmaceuticals, Neurology Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 21, 2017 Category: Pharmaceuticals Source Type: news